Capsul Desk writes each daily edition. We are senior reporters and editors from Norstella's News and Insights division, with decades covering the industry's full arc, from a molecule's first trial to the pricing fight that decides who can afford it.
Aphaia's obesity data leads the pack, Connect's acute-asthma topline lands in September, Kyverna's CAR-T filing by year end. What each result decides, and who's waiting to write the check.
Carboplatin and cisplatin sit in the comparator arms of the oncology studies meant to replace them. ASCO's chief medical officer says a missing generic can halt a trial and delay the approval behind it.
Today is a quiet kind of vindication story, the sort the industry doesn't hand out often. A founder spent 15 years insisting that the junk stretches of the
France fined Novo Nordisk and Eli Lilly for obesity "awareness" campaigns that, it ruled, were illegal ads. The sums are trivial. The precedent is not: a campaign that never names the drug can still count as promoting it, and India is already further down the same road.
Novo's denecimig heads into US and European decisions this quarter as a once-monthly rival to Roche's Hemlibra, while Incyte and Hemab try to give von Willebrand patients the convenient prophylaxis hemophilia A already takes for granted.
A strong start to the year, booming M&A, and the tariff and pricing worries off the boil. The question, starting with J&J on Wednesday, is whether the cautious 2026 forecasts get raised.
The best oncology assets draw a crowd and a price to match. Bayer's answer is a courtship, not an auction: it gets to know the founders years before there's a deal, and stays in touch even after a no.
More than 30 candidates are chasing hypertension, high Lp(a), and dyslipidemia, markets far larger than the rare diseases that built the field. Whether it works turns on outcomes trials over the next two to four years, and on pricing.
Many of the assets came out of Chinese labs, and much of the money behind them rides on science still years from proving out.
Money is everywhere and buyers are hungry, so biotechs are seeing several suitors at once and in no rush to commit. The complications: the most wanted assets keep turning up in China, and a US pricing rule means no deal abroad stays abroad.
